These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 25499759)

  • 1. Loss of PRDM11 promotes MYC-driven lymphomagenesis.
    Fog CK; Asmar F; Côme C; Jensen KT; Johansen JV; Kheir TB; Jacobsen L; Friis C; Louw A; Rosgaard L; Øbro NF; Marquart HV; Anthonsen K; Braat AK; van Lohuizen M; Ralfkiaer E; Grønbæk K; Lund AH
    Blood; 2015 Feb; 125(8):1272-81. PubMed ID: 25499759
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activating and sustaining c-Myc by depletion of miR-144/451 gene locus contributes to B-lymphomagenesis.
    Ding L; Zhang Y; Han L; Fu L; Mei X; Wang J; Itkow J; Elabid AEI; Pang L; Yu D
    Oncogene; 2018 Mar; 37(10):1293-1307. PubMed ID: 29284789
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Myc suppression of Nfkb2 accelerates lymphomagenesis.
    Keller U; Huber J; Nilsson JA; Fallahi M; Hall MA; Peschel C; Cleveland JL
    BMC Cancer; 2010 Jul; 10():348. PubMed ID: 20598117
    [TBL] [Abstract][Full Text] [Related]  

  • 4. E6AP ubiquitin ligase regulates PML-induced senescence in Myc-driven lymphomagenesis.
    Wolyniec K; Shortt J; de Stanchina E; Levav-Cohen Y; Alsheich-Bartok O; Louria-Hayon I; Corneille V; Kumar B; Woods SJ; Opat S; Johnstone RW; Scott CL; Segal D; Pandolfi PP; Fox S; Strasser A; Jiang YH; Lowe SW; Haupt S; Haupt Y
    Blood; 2012 Jul; 120(4):822-32. PubMed ID: 22689861
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Apaf-1 and caspase-9 do not act as tumor suppressors in myc-induced lymphomagenesis or mouse embryo fibroblast transformation.
    Scott CL; Schuler M; Marsden VS; Egle A; Pellegrini M; Nesic D; Gerondakis S; Nutt SL; Green DR; Strasser A
    J Cell Biol; 2004 Jan; 164(1):89-96. PubMed ID: 14709542
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development and survival of MYC-driven lymphomas require the MYC antagonist MNT to curb MYC-induced apoptosis.
    Nguyen HV; Vandenberg CJ; Ng AP; Robati MR; Anstee NS; Rimes J; Hawkins ED; Cory S
    Blood; 2020 Mar; 135(13):1019-1031. PubMed ID: 31978211
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined loss of PUMA and p21 accelerates c-MYC-driven lymphoma development considerably less than loss of one allele of p53.
    Valente LJ; Grabow S; Vandenberg CJ; Strasser A; Janic A
    Oncogene; 2016 Jul; 35(29):3866-71. PubMed ID: 26640149
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cyclin-Dependent Kinase-9 Is a Therapeutic Target in MYC-Expressing Diffuse Large B-Cell Lymphoma.
    Hashiguchi T; Bruss N; Best S; Lam V; Danilova O; Paiva CJ; Wolf J; Gilbert EW; Okada CY; Kaur P; Drew L; Cidado J; Hurlin P; Danilov AV
    Mol Cancer Ther; 2019 Sep; 18(9):1520-1532. PubMed ID: 31243099
    [TBL] [Abstract][Full Text] [Related]  

  • 9. p53 and p73 in suppression of Myc-driven lymphomagenesis.
    Griesmann H; Schlereth K; Krause M; Samans B; Stiewe T
    Int J Cancer; 2009 Jan; 124(2):502-6. PubMed ID: 18942718
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MYC selects against reduced BCL2A1/A1 protein expression during B cell lymphomagenesis.
    Sochalska M; Schuler F; Weiss JG; Prchal-Murphy M; Sexl V; Villunger A
    Oncogene; 2017 Apr; 36(15):2066-2073. PubMed ID: 27694901
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Addiction to Runx1 is partially attenuated by loss of p53 in the Eµ-Myc lymphoma model.
    Borland G; Kilbey A; Hay J; Gilroy K; Terry A; Mackay N; Bell M; McDonald A; Mills K; Cameron E; Neil JC
    Oncotarget; 2016 Apr; 7(17):22973-87. PubMed ID: 27056890
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A transgenic mouse model demonstrating the oncogenic role of mutations in the polycomb-group gene EZH2 in lymphomagenesis.
    Berg T; Thoene S; Yap D; Wee T; Schoeler N; Rosten P; Lim E; Bilenky M; Mungall AJ; Oellerich T; Lee S; Lai CK; Umlandt P; Salmi A; Chang H; Yue L; Lai D; Cheng SW; Morin RD; Hirst M; Serve H; Marra MA; Morin GB; Gascoyne RD; Aparicio SA; Humphries RK
    Blood; 2014 Jun; 123(25):3914-24. PubMed ID: 24802772
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Myc-mediated proliferation and lymphomagenesis, but not apoptosis, are compromised by E2f1 loss.
    Baudino TA; Maclean KH; Brennan J; Parganas E; Yang C; Aslanian A; Lees JA; Sherr CJ; Roussel MF; Cleveland JL
    Mol Cell; 2003 Apr; 11(4):905-14. PubMed ID: 12718877
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Deletion of the transcriptional regulator TFAP4 accelerates c-MYC-driven lymphomagenesis.
    Potts MA; Mizutani S; Garnham AL; Li Wai Suen CSN; Kueh AJ; Tai L; Pal M; Strasser A; Herold MJ
    Cell Death Differ; 2023 Jun; 30(6):1447-1456. PubMed ID: 36894688
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of ADGRE5 as discriminating MYC target between Burkitt lymphoma and diffuse large B-cell lymphoma.
    Kleo K; Dimitrova L; Oker E; Tomaszewski N; Berg E; Taruttis F; Engelmann JC; Schwarzfischer P; Reinders J; Spang R; Gronwald W; Oefner PJ; Hummel M
    BMC Cancer; 2019 Apr; 19(1):322. PubMed ID: 30953469
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oncogenic c-Myc-induced lymphomagenesis is inhibited non-redundantly by the p19Arf-Mdm2-p53 and RP-Mdm2-p53 pathways.
    Meng X; Carlson NR; Dong J; Zhang Y
    Oncogene; 2015 Nov; 34(46):5709-17. PubMed ID: 25823025
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BCL-W has a fundamental role in B cell survival and lymphomagenesis.
    Adams CM; Kim AS; Mitra R; Choi JK; Gong JZ; Eischen CM
    J Clin Invest; 2017 Feb; 127(2):635-650. PubMed ID: 28094768
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    Mathsyaraja H; Freie B; Cheng PF; Babaeva E; Catchpole JT; Janssens D; Henikoff S; Eisenman RN
    Genes Dev; 2019 Sep; 33(17-18):1252-1264. PubMed ID: 31395740
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evidence for an oncogenic modifier role for mutant histone acetyltransferases in diffuse large B-cell lymphoma.
    Haery L; Mussakhan S; Waxman DJ; Gilmore TD
    Leuk Lymphoma; 2016 Nov; 57(11):2661-71. PubMed ID: 27003102
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Suppression of Myc oncogenic activity by nucleostemin haploinsufficiency.
    Zwolinska AK; Heagle Whiting A; Beekman C; Sedivy JM; Marine JC
    Oncogene; 2012 Jul; 31(28):3311-21. PubMed ID: 22081066
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.